User profiles for "author:Melanie Greenland"
 | Melanie GreenlandUniversity of Oxford Verified email at paediatrics.ox.ac.uk Cited by 9070 |
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Summary Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for
emergency use by the UK regulatory authority, Medicines and Healthcare products …
emergency use by the UK regulatory authority, Medicines and Healthcare products …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B. 1.1. 7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in …
ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
RH Shaw, A Stuart, M Greenland, X Liu, JSN Van-Tam… - The Lancet, 2021 - thelancet.com
There is significant international interest in heterologous prime-boost COVID-19 vaccination
to mitigate against supply shocks or shortages that might otherwise reduce the speed of …
to mitigate against supply shocks or shortages that might otherwise reduce the speed of …
[HTML][HTML] Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial
Background Typhoid fever remains a major cause of morbidity and mortality in low-income
and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended …
and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended …
[HTML][HTML] Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial
Background In women with late preterm pre-eclampsia, the optimal time to initiate delivery is
unclear because limitation of maternal disease progression needs to be balanced against …
unclear because limitation of maternal disease progression needs to be balanced against …
Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN‐SPIDERS
LL Dalli, MF Kilkenny, I Arnet… - British Journal of …, 2022 - Wiley Online Library
Although medication adherence is commonly measured in electronic datasets using the
proportion of days covered (PDC), no standardized approach is used to calculate and report …
proportion of days covered (PDC), no standardized approach is used to calculate and report …
Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change
JM Katzenellenbogen, D Bond‐Smith… - Journal of the …, 2020 - Am Heart Assoc
Background In 2018, the World Health Organization prioritized control of acute rheumatic
fever (ARF) and rheumatic heart disease (RHD), including disease surveillance. We …
fever (ARF) and rheumatic heart disease (RHD), including disease surveillance. We …
[HTML][HTML] Safety and immunogenicity report from the com-COV study–a single-blind randomised non-inferiority trial comparing heterologous and homologous prime …
X Liu, RH Shaw, ASV Stuart, M Greenland, T Dinesh… - 2021 - papers.ssrn.com
Background: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation, however we have previously reported that heterologous …
mass COVID-19 immunisation, however we have previously reported that heterologous …